US Stock MarketDetailed Quotes
XFOR X4 Pharmaceuticals
- 0.759
- +0.011+1.47%
Close Jul 19 16:00 ET
127.46MMarket Cap-1132P/E (TTM)
0.763High0.728Low978.69KVolume0.763Open0.748Pre Close728.57KTurnover0.77%Turnover RatioLossP/E (Static)167.94MShares1.84052wk High126.50P/B97.06MFloat Cap0.53152wk Low--Dividend TTM127.88MShs Float23.930Historical High--Div YieldTTM4.68%Amplitude0.531Historical Low0.744Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
X4 Pharmaceuticals Stock Forum
Xolremdi sales report next month.
holy shit
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
X4 Pharmaceuticals (Nasdaq: XFOR) will host a virtual investor event on June 27, 2024, at 8:00 AM ET to present new interim results from a Phase 2 clinical trial on mavorixafor for treating chronic neutropenia (CN).
The webcast will showcase hematological data from at least 15 participants, treated either wi...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
No comment yet